Results 161 to 170 of about 1,442,988 (353)

Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (EMB‐02) in Patients With Advanced Solid Tumors

open access: yesCPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Fanastomig (also known as EMB‐02) is a bispecific antibody targeting programmed cell death protein‐1(PD‐1) and lymphocyte activation gene‐3 (LAG‐3), developed for the treatment of advanced solid tumors. A first‐in‐human (FIH) Phase I study (NCT04618393) evaluated safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD ...
Chengjun Jiang   +6 more
wiley   +1 more source

Bayesian Optimization of Antibodies Informed by a Generative Model of Evolving Sequences [PDF]

open access: yesarXiv
To build effective therapeutics, biologists iteratively mutate antibody sequences to improve binding and stability. Proposed mutations can be informed by previous measurements or by learning from large antibody databases to predict only typical antibodies.
arxiv  

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2

open access: green, 1994
B. J. Kroesen   +7 more
openalex   +2 more sources

Anti-CD3/Anti-Epidermal Growth Factor Receptor-Bispecific Antibody Retargeting of Lymphocytes against Human Neoplastic Keratinocytes in an Autologous Organotypic Culture Model [PDF]

open access: green, 2002
Isabelle Renard   +6 more
openalex   +1 more source

A Model‐Based Approach to Evaluate Anti‐Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T‐Cell Bispecific Cibisatamab

open access: yesCPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT The administration of biologics can lead to immunogenic responses that trigger anti‐drug antibody (ADA) formation. ADAs can decrease drug exposure. A population pharmacokinetic (popPK) model was developed to describe clinical PK data with and without ADA‐driven exposure loss with CEA‐directed T‐cell bispecific antibody cibisatamab.
Javier Sanchez   +6 more
wiley   +1 more source

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives

open access: yesFrontiers in Oncology
Patients with relapsed/refractory multiple myeloma (RRMM) that are refractory to the five most active anti-MM drugs, so-called penta-refractory MM, have historically had dismal outcomes with subsequent therapies.
Ricardo D. Parrondo   +2 more
doaj   +1 more source

Relation-Aware Equivariant Graph Networks for Epitope-Unknown Antibody Design and Specificity Optimization [PDF]

open access: yesarXiv
Antibodies are Y-shaped proteins that protect the host by binding to specific antigens, and their binding is mainly determined by the Complementary Determining Regions (CDRs) in the antibody. Despite the great progress made in CDR design, existing computational methods still encounter several challenges: 1) poor capability of modeling complex CDRs with
arxiv  

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer [PDF]

open access: hybrid, 2003
Roland Repp   +14 more
openalex   +1 more source

Development of a Heuristic Machine Analogy Method for Model Simplification With an Application to a Large‐Scale Model of Gi/Gs Signaling

open access: yesCPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Model simplification is a process to simplify large‐scale mathematical models to enable easy applications such as simulation and parameter estimation. A novel heuristic machine analogy method of model simplification was developed and applied to a motivating example of a model for cAMP signaling switch induced by Gi/Gs pathway competition for ...
Liang Yang   +3 more
wiley   +1 more source

Intradiabodies, Bispecific, Tetravalent Antibodies for the Simultaneous Functional Knockout of Two Cell Surface Receptors [PDF]

open access: hybrid, 2003
Nina Jendreyko   +6 more
openalex   +1 more source

Home - About - Disclaimer - Privacy